Literature DB >> 15596668

Benchmarking lung cancer mortality rates in current and former smokers.

Peter B Bach1, Elena B Elkin, Ugo Pastorino, Michael W Kattan, Alvin I Mushlin, Colin B Begg, D Maxwell Parkin.   

Abstract

STUDY
OBJECTIVES: To develop and validate a model for estimating the risk of lung cancer death in current and former smokers. The model is intended for use in analyzing a population of subjects who are undergoing lung cancer screening or receiving lung cancer chemoprevention, to determine whether the intervention has altered lung cancer mortality. DESIGN/SETTING/PATIENTS: Model derivation was based on analyses of the placebo arm of the Carotene and Retinol Efficacy Trial. Model validation was based on analyses of three other longitudinal cohorts. MEASUREMENTS: Observed and predicted number of deaths due to lung cancer.
RESULTS: In internal validation, the model was highly concordant and well calibrated. In external validation, the model predictions were similar to what was observed in all of the validation analyses. The predicted and observed deaths within 6 years were very similar when assessed in the Johns Hopkins Hospital trial of chest radiography and sputum cytology screening (176 predicted, 184 observed, p = 0.53), the Memorial Sloan-Kettering Cancer Center trial of chest radiography and sputum cytology screening (108 predicted, 114 observed, p = 0.57), and the National Health and Nutrition Evaluation Survey part I (24 predicted, 21 observed, p = 0.52).
CONCLUSIONS: The number of lung cancer deaths in a population of current or former smokers can be accurately predicted, making model-based evaluations of prevention and early detection interventions a useful adjunct to definitive randomized trials. We illustrate this potential use with a small example.

Entities:  

Mesh:

Year:  2004        PMID: 15596668     DOI: 10.1378/chest.126.6.1742

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  18 in total

Review 1.  Lung cancer screening: an update, discussion, and look ahead.

Authors:  Peter J Mazzone
Journal:  Curr Oncol Rep       Date:  2010-07       Impact factor: 5.075

2.  Anti-Oligomannose Antibodies as Potential Serum Biomarkers of Aggressive Prostate Cancer.

Authors:  Denong Wang; Laila Dafik; Rosalie Nolley; Wei Huang; Russell D Wolfinger; Lai-Xi Wang; Donna M Peehl
Journal:  Drug Dev Res       Date:  2013-03       Impact factor: 4.360

Review 3.  Lung cancer screening.

Authors:  Peter J Mazzone; Tarek Mekhail
Journal:  Curr Oncol Rep       Date:  2007-07       Impact factor: 5.075

4.  Re: Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk.

Authors:  Margaret R Spitz; C I Amos; A D'Amelio; Q Dong; C Etzel
Journal:  J Natl Cancer Inst       Date:  2009-12-16       Impact factor: 13.506

5.  Bridging the etiologic and prognostic outlooks in individualized assessment of absolute risk of an illness: application in lung cancer.

Authors:  Igor Karp; Marie-Pierre Sylvestre; Michal Abrahamowicz; Karen Leffondré; Jack Siemiatycki
Journal:  Eur J Epidemiol       Date:  2016-07-11       Impact factor: 8.082

6.  Comparison of Observed Harms and Expected Mortality Benefit for Persons in the Veterans Health Affairs Lung Cancer Screening Demonstration Project.

Authors:  Tanner J Caverly; Angela Fagerlin; Renda Soylemez Wiener; Christopher G Slatore; Nichole T Tanner; Shira Yun; Rodney Hayward
Journal:  JAMA Intern Med       Date:  2018-03-01       Impact factor: 21.873

7.  Implications of Nine Risk Prediction Models for Selecting Ever-Smokers for Computed Tomography Lung Cancer Screening.

Authors:  Hormuzd A Katki; Stephanie A Kovalchik; Lucia C Petito; Li C Cheung; Eric Jacobs; Ahmedin Jemal; Christine D Berg; Anil K Chaturvedi
Journal:  Ann Intern Med       Date:  2018-05-15       Impact factor: 25.391

8.  An official American Thoracic Society/American College of Chest Physicians policy statement: implementation of low-dose computed tomography lung cancer screening programs in clinical practice.

Authors:  Renda Soylemez Wiener; Michael K Gould; Douglas A Arenberg; David H Au; Kathleen Fennig; Carla R Lamb; Peter J Mazzone; David E Midthun; Maryann Napoli; David E Ost; Charles A Powell; M Patricia Rivera; Christopher G Slatore; Nichole T Tanner; Anil Vachani; Juan P Wisnivesky; Sue H Yoon
Journal:  Am J Respir Crit Care Med       Date:  2015-10-01       Impact factor: 21.405

Review 9.  American Cancer Society lung cancer screening guidelines.

Authors:  Richard Wender; Elizabeth T H Fontham; Ermilo Barrera; Graham A Colditz; Timothy R Church; David S Ettinger; Ruth Etzioni; Christopher R Flowers; G Scott Gazelle; Douglas K Kelsey; Samuel J LaMonte; James S Michaelson; Kevin C Oeffinger; Ya-Chen Tina Shih; Daniel C Sullivan; William Travis; Louise Walter; Andrew M D Wolf; Otis W Brawley; Robert A Smith
Journal:  CA Cancer J Clin       Date:  2013-01-11       Impact factor: 508.702

10.  The risk of death by age, sex, and smoking status in the United States: putting health risks in context.

Authors:  Steven Woloshin; Lisa M Schwartz; H Gilbert Welch
Journal:  J Natl Cancer Inst       Date:  2008-06-10       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.